Ambit Biosciences Corporation

Signal Pharmaceuticals, Inc.

Cephalon, Inc.

Ipsen Pharma S.a.s.

Biomarin Pharmaceutical Inc.

Estryx Pharma Limited

Ambit Bioscience Corporation

Qi Chao

Shripad S Bhagwat

Mark W Holladay

Kelly G Sprankle

Eduardo Setti

Sunny Abraham

Martin W Rowbottom

Andiliy Gokching Lai

Brian T Campbell

Raffaella Faraoni

John J Sapienza

Yoshitaka Satoh

Chris Allen Buhr

Ronald J Albers

Steven T Sakata

Kiran Sahasrabudhe

Leah Marie Gayo-Fung

Veronique Plantevin

Rachel Ferri

Gang Liu

Serge Auvin

Kenneth D Rice

Bernd M Stein

Michael J Hadd

Jeffrey A McKie

Anthony R Gangloff

Hitesh K Patel

Robert M Grotzfeld

Gary Elliott

Christophe Lanco

Lorenzo Leoni

Kaichun Gu

Bing Wang

Olivier Lavergne

Yufeng Chen

Oliver Dutruel

Mimi K Phillips

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Glycolate oxidase inhibitors for the treatment of disease

Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

RAF kinase modulator compounds and methods of use thereof

Imidazolidine-2,4-dione derivatives of formula (I): These compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation, such as cancer.

Imidazolidine-2,4-dione dervatives

The present invention relates to new biphenyl derivatives of formula These compounds acting as aromatase and sulfatase inhibitors, they are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved. Moreover, the present invention provides processes for the preparation of these compounds. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament, in particular for the treatment of diseases characterized by aromatase and sulfatase activity such as hormone-dependent cancers.

Substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase

Imidazolidine-2,4-dione derivatives of formula (I):  The compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation such as cancer.

Imidazolidine-2,4-dione derivatives

Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

Provided herein are quinazoline compounds of formula (I):  The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

JAK kinase modulating compounds and methods of use thereof

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Imidazolothiazole compounds for the treatment of disease

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O); Ris O or S. 

Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Method of using imidazolothiazole compounds for the treatment of disease

Growing community of inventors

San Diego, CA, United States of America

Qi Chao